NEK10

Across TCGA pan-cancer cohorts, NEK10 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of NEK10’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where NEK10 RNA is repressed in tumor relative to normal tissue. In most cancer types NEK10 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and LUSC are the cancer types where NEK10 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in NEK10 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	III,IV	−0.404	<.001	11	view →
KIRC	All	II,III,IV	−0.276	<.001	11	view →
LUSC	All	II,III,IV	−0.933	<.001	6	view →
LUAD	All	All	−0.527	.001	6	view →
BRCA	Female	All	−0.495	.011	4	view →
KICH	All	All	−0.396	<.001	4	view →
READ	All	All	−0.491	.008	2	view →
HNSC	Male	All	−0.279	.015	2	view →
CHOL	Female	All	−0.266	.010	1	view →
STAD	Male	IV	−0.140	.012	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

NEK10–THCA

Open the THCA breakdown →